Is it realistic that given the high expectations for cyprotex that it could reach 3 per share. Partnerships with the big pharma co's could make these shoot north?

Thanks PT and BA. I've seen the health warnings that Trader6 had posted here - and BA's lovely plumbing comments; have not the slightest intention of throwing my money away here. Just thought, though, that something should be written to make others think, in case they were blissfully unaware of what you guys already know from experience.

Fundraising Aug08
40million shares - shareholders appear to have subscribed to just 40% - not sure if that's bad - but dilution stalks. . . . . the fundraising collected 1m.
How long will that last, I wonder? + will the Institutions be leaking unsubscribed Stock, creating sp ceiling for a while.
Today sp up a tad, off Lows- but I do wonder?

Is this a stock for feel-good times?

It's not as though they are likely to discover something for the benefit of their own shareholders.....that's where the problem lies....plus most Bios will want to do the easy-bits themselves, I guess.

Worth a look and a longish hold.

I have held these at a loss for over 4years. I thought their model would be useful and "hoped" they would come good.

From the results they are doing so and I think continue to do so.

Difficult to judge, but the company has cash in hand and growth rate should improve rapidly, even in the present environment.

But DYOH

Financial Highlights
Extract from today's RNS

Notwithstanding the significant management changes that took place during the year, the Company has recorded a very progressive financial performance.


*

Revenue for the period increased by 43% to 5.18 million
*

Gross profits rose by 49% to 4.48 million from 3.00 million in 2007
*

Operating profit was positive for the first time in the Company's history at 567,000 against a loss of 496,000 in 2007
*

Earnings per share of 0.36 pence (2007: loss per share of 0.35 pence)
*

Successful fully subscribed Placing and Open Offer raised 1.00 million (0.97 million net of costs)
*

Notwithstanding continuing investment, the year end cash position improved significantly to 1.58 million from the low point recorded at the half year to 30 June 2008 of 0.28 million


New Product and Facilities Development


During the year, the Company undertook a full review of the products and services it offers with several of its largest customers. As a result of that feedback, we have invested in Research and Development programmes and in capital investments to improve both our range of assays and our equipment base. Such investment has been moribund in recent years. The following represents some of the new assays and facilities that have been implemented in 2008 / early 2009.


*

Two new laboratories (720 sq ft in total) have been built and fitted out at our Beech Lane facilities at a total cost of 125,000. These new facilities provide room for a potential further 15 staff and were officially opened in February 2009 by Sir Nicholas Winterton MP DL
*

Early in 2009 a new ABI Sciex QTRAP mass spectrometer was installed at a cost of 250,000. This instrument offers up to 10,000 times greater sensitivity in detection of samples
*

In April 2008, we launched a new product line, Cloe Select, which enables the Company to offer more bespoke, customised assays for our clients. Revenues from this service have steadily risen during the year
*

A new product catalogue was launched in April 2008
*

We have enhanced our range of drug-drug interaction screens. These include introducing our Cloe Select P-gp inhibition assay and extending the number of isoforms in our panel of CYP inhibition screens


These new facilities and assays have been well received by our customers and are already generating new revenue for the business.


We are currently working on development programmes to more fully commercially exploit our software services. We intend to launch an innovative and novel pay-per-use service through a new web based portal called Cloe Gateway. Further investments are planned during 2009.